Effects of different gastrointestinal reconstruction methods after distal subtotal gastrectomy on nutritional status and blood glucose in patients with type 2 diabetes and gastric cancer
10.3760/cma.j.issn.1674-6090.2014.06.006
- VernacularTitle:不同消化道重建术式对2型糖尿病胃癌患者术后营养状况及血糖的影响
- Author:
Chao HE
;
Gang CUI
- Publication Type:Journal Article
- Keywords:
Type II diabetes mellitus;
Gastric cancer;
Gastrointestinal reconstruction;
Roux-en-Y;
Nutrition;
Glycemic metabolism
- From:
Journal of Endocrine Surgery
2014;(6):459-462
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of different gastrointestinal reconstruction methods after dis -tal subtotal gastrectomy on nutritional condition and blood glucose in patients with type 2 diabetes ( T2DM) and gastric cancer.Methods 88 patients with T2DM and gastric cancer undergoing radial distal gastrectomy were studied and among them 43 patients had Billroth I gastrointestinal reconstruction , 22 patients had Billroth II gas-trointestinal reconstruction and 23 patients had Roux-en-Y gastrointestinal reconstruction .Body mass index ( BMI) , serum albumin and prealbumin of the 3 groups were measured preoperatively and 1 year after surgery . The patients were followed up .Results There was no significant difference among the 3 groups in preoperative values(P>0.05).One year after surgery, BMI, serum albumin and peralbumin in the 3 groups had different de-grees of reduction , but showed no statistical difference ( P>0.05 ) .The effective rate of diabetes control was 18.60%in Billroth I group , 72.73%in Billroth II group , and 73.91% in Roux-en-Y group and the difference had statistical significance(χ2 =17.390 3,P<0.05).The effective rates of diabetes control in Billroth II group and Roux-en-Y group were higher than that in Billroth I group (χ2 =18.340 9,P<0.05;χ2 =19.480 4,P<0.05), and there was no evident difference between Billroth II group and Roux-en-Y group(χ2 =0.008 1,P=0.928 4).Conclusion Billroth II and Roux-en-Y gastrointestinal reconstruction can improve glycemic metabo-lism of patients with T2DM and gastric cancer without significantly reducing the nutrition status .
